D. E. Shaw & Co., Inc. Prelude Therapeutics Inc Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.74 - $4.79 $18,231 - $31,872	-6,654 Reduced 11.92%	49,184 $151,000
Q2 2023 Aug 14, 2023	BUY	$4.45 - $8.12 $38,221 - $69,742	8,589 Added 18.18%	55,838 $251,000
Q1 2023 May 15, 2023	SELL	$4.58 - $7.34 $95,062 - $152,349	-20,756 Reduced 30.52%	47,249 $269,000
Q4 2022 Feb 14, 2023	SELL	$4.61 - $8.5 $50,138 - $92,446	-10,876 Reduced 13.79%	68,005 $410,000
Q3 2022 Nov 14, 2022	SELL	$5.0 - $8.82 $184,930 - $326,216	-36,986 Reduced 31.92%	78,881 $521,000
Q2 2022 Aug 15, 2022	BUY	$4.0 - $7.55 $369,024 - $696,532	92,256 Added 390.73%	115,867 $605,000
Q1 2022 May 16, 2022	BUY	$6.9 - $13.22 $162,915 - $312,137	23,611 New	23,611 $163,000
Q2 2021 Aug 16, 2021	SELL	$28.63 - $44.3 $359,191 - $555,787	-12,546 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$39.27 - $91.68 $492,681 - $1.15 Million	12,546 New	12,546 $544,000

35.7M

500

300

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $34.2M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.